



ELSEVIER

CORRIGENDUM



Corrigendum to “The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent Adults” [J Infect 72 (2016) 405–438][☆]

F. McGill^{a,b,c,d,* ,x}, R.S. Heyderman^{e,x}, B.D. Michael^{a,f,y},
S. Defres^{a,c,v,x}, N.J. Beeching^{a,b,c,g,x}, R. Borrow^{h,ab},
L. Glennie^{w,ac}, O. Gaillemain^{j,aa}, D. Wyncoll^{q,z},
E. Kaczmarek^{k,ab}, S. Nadel^{m,n,ac}, G. Thwaites^{p,u,x}, J. Cohen^{t,x},
N.W.S. Davies^{i,y}, A. Miller^{a,l,x}, A. Rhodes^{o,z}, R. Read^{r,s,x},
T. Solomon^{a,b,c,f,y}

^a Institute of Infection and Global Health, University of Liverpool, UK

^b National Institute for Health Research Health Protection Research Unit on Emerging and Zoonotic Infections, UK

^c Royal Liverpool and Broadgreen University Hospitals NHS Trust, UK

^d Leeds Teaching Hospitals NHS Trust, UK

^e Division of Infection & Immunity, University College London, UK

^f Walton Centre NHS Foundation Trust, Liverpool, UK

^g Liverpool School of Tropical Medicine, UK

^h Vaccine Evaluation Unit, Public Health England, Manchester, UK

ⁱ Chelsea and Westminster Hospital NHS Foundation Trust, UK

^j Salford Royal NHS Foundation Trust, UK

^k Public Health England, UK

^l North Cumbria University Hospitals NHS Trust, UK

DOI of original article: <http://dx.doi.org/10.1016/j.jinf.2016.01.007>

[☆] Endorsed by the Royal College of Emergency Medicine, UK.

* Corresponding author. Institute of Infection and Global Health, Ronald Ross Building, University of Liverpool, 8 West Derby Street, Liverpool, L69 7BE, UK. Tel.: +44 0151 795 9606.

E-mail address: fmcgill@liv.ac.uk (F. McGill).

^x On behalf of the British Infection Association.

^y On behalf of the Association of British Neurologists.

^z On behalf of the Intensive Care Society.

^{aa} On behalf of the Society for Acute Medicine.

^{ab} On behalf of Public Health England.

^{ac} On behalf of the Meningitis Research Foundation.

<http://dx.doi.org/10.1016/j.jinf.2016.04.001>

0163-4453/© 2016 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

^m St Mary's Hospital, London, UK

ⁿ Imperial College, London, UK

^o St Georges University Hospitals NHS Foundation Trust, UK

^p Nuffield Department of Medicine, Oxford University, UK

^q Guy's and St Thomas' NHS Foundation Trust, UK

^r Clinical and Experimental Sciences Unit, University of Southampton, UK

^s University Hospital Southampton NHS Foundation Trust, UK

^t Brighton and Sussex Medical School, Brighton, UK

^u Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

^v NHS Tayside, UK

^w Meningitis Research Foundation, Bristol, UK

The authors regret the following footnote should have been included with Table 6:

In cases where Chloramphenicol is used (known anaphylaxis to penicillins or cephalosporins) the dose may be reduced to 12.5 mg/kg 6 hourly if the patient is recovering, to reduce the risk of a dose-related anaemia.

Table 6 is reproduced again here with the addition of the footnote.

The authors would like to apologise for any inconvenience caused.

Table 6 Definitive antibiotic treatment.

Aetiology	Antibiotic (s)	Dose	Alternative antibiotic choices	Dose	Duration ^b
<i>Neisseria meningitidis</i>	Cefotaxime	2 g 6 hourly/2 g	Chloramphenicol (if anaphylaxis) OR Benzylpenicillin	25 mg/kg	5 days
	OR Ceftriaxone	12 hourly		6 hourly	
<i>Streptococcus pneumoniae</i> (sensitivities unknown or penicillin resistant, cephalosporin sensitive)	Cefotaxime ^a	2 g 6 hourly	Chloramphenicol	25 mg/kg	10 days (if stable) Up to 14 days if taking longer to respond
	OR Ceftriaxone ^a	2 g 12 hourly		6 hourly	
<i>Streptococcus pneumoniae</i> (penicillin sensitive, MIC ≤ 0.06)	Benzylpenicillin	2.4 g 4 hourly	Chloramphenicol	25 mg/kg	10 days (if stable) Up to 14 days if taking longer to respond
	OR Cefotaxime	2 g 6 hourly/2 g		6 hourly	
	OR Ceftriaxone ^c	12 hourly			
<i>Streptococcus pneumoniae</i> (penicillin and cephalosporin non-susceptible, penicillin MIC > 0.06 or cefotaxime/ceftriaxone MIC > 0.5)	Cefotaxime	2 g 6 hourly	Chloramphenicol ^e	25 mg/kg	14 days
	OR Ceftriaxone	2 g 12 hourly		6 hourly	
	AND Vancomycin ^d	15–20 mg/kg			
	OR Rifampicin	12 hourly (adjusting according to serum trough levels)			
		600 mg bd			
<i>Listeria monocytogenes</i>	Amoxicillin	2 g 4 hourly	Co-trimoxazole	10–20 mg/kg (of the trimethoprim component) in 4 divided doses	21 days
<i>Haemophilus influenzae</i>	Cefotaxime	2 g 6 hourly	Moxifloxacin	400 mg od	10 days
	OR Ceftriaxone	2 g 12 hourly			

^a Add in IV Vancomycin 15–20 mg/kg bd or Rifampicin 600 mg bd if penicillin resistance is suspected e.g. patient has recently arrived from a country where penicillin resistant pneumococci is prevalent (if unsure, check with local infectious diseases/microbiology expertise).

^b Treatment durations may need to be extended if patient is not responding.

^c If low risk of *Clostridium difficile* infection and/or requiring outpatient therapy.

^d Serum vancomycin trough concentrations of 15–20 µg/ml should be aimed for.

^e In cases where Chloramphenicol is used (known anaphylaxis to penicillins or cephalosporins) the dose may be reduced to 12.5 mg/kg 6 hourly if the patient is recovering, to reduce the risk of a dose-related anaemia.